Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex

Targeting the dysregulated BRaf-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRaf and MEK, resistance develops often involving non-genomic adaptive bypass mechanisms. Inhibition of MEK1/2 by tra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Autores principales: Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U., Chen, Xin, Duncan, James S., Whittle, Martin C., Angus, Steven P., Velarde, Sara Hanna, Golitz, Brian T., He, Xiaping, Santos, Charlene, Darr, David B., Gallagher, Kristalyn, Graves, Lee M., Perou, Charles M., Carey, Lisa A., Earp, H. Shelton, Johnson, Gary L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340640/
https://ncbi.nlm.nih.gov/pubmed/28108460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0653
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares